By Philip Ball of Nature magazine
Chemists have succeeded in synthesizing a natural compound that shows promise as a painkiller--and might not cause the side effects that bedevil analgesics currently used to treat acute and chronic conditions.
Conolidine is found in the bark of the tropical flowering shrub Tabernaemontana divaricata, commonly called the pinwheel flower. The plant is native to southeast Asia, where it has long been used in traditional Chinese, Ayurvedic and Thai medicines to treat fever and pain.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
But the shrubs contain so little of the compound that pharmacologists have been unable to study its medicinal applications. Now, a team at the Scripps Research Institute in Jupiter, Florida, has made conolidine in the lab from simple starting materials, and found that it has analgesic effects. The researchers describe their findings in a paper published today in Nature Chemistry.
T. divaricata contains a range of 'alkaloid' compounds, the molecules of which have carbon-based frameworks in which the atoms are linked into several rings. Some of these have already been studied as candidate drugs, but they are opioids, belonging to the same class of compounds as morphine and hydrocone.
Opioids cause serious side effects, including addiction, nausea and breathing problems. Conolidine is not an opioid, so it might offer pain relief without these complications.
Steps to success
However, Glenn Micalizio, a chemist at Scripps, and his colleagues did not become interested in the compound because of its pharmaceutical potential. Rather, they realized that its complex carbon skeleton was an ideal target for testing a type of reaction that they had recently devised.
Although putting together the complex frameworks of natural molecules is a well developed art, each molecule poses its own unique challenges. "This ring system is particularly challenging," says Micalizio.
The team worked out how to make an intermediate molecule in which the shape of the carbon skeleton led to easy forging of the final link in the network of rings--in other words, a structure with loose ends dangling close to one another in more or less the right configuration.
The conolidine molecule has two mirror-image versions, both of which the authors made starting with the same commercially available molecule. They first converted this reagent into two mirror-image forms, which they separated using an enzyme capable of telling them apart.
A further eight steps brought them to their target. Each step in a synthesis inevitably produces some side products, so not all of the starting material ends up as conolidine. But 18% of it does--a respectable proportion for a complicated synthesis.
Pain drain
It was only after working out how to make the molecule that Micalizio's team decided to approach Laura Bohn, a pharmacologist at Scripps, to investigate its biological effects. Although researchers had been aware of the analgesic effects of similar compounds, it hadn't previously been possible to investigate conolidine, because there wasn't enough of the compound available from the natural source for testing. It makes up just 0.00014% of the bark of T. divaricata.
In trials with mice, Bohn and her colleagues established that the synthetic conolidine reduces inflammatory pain. What's more, there is evidence that it does so using a different biological pathway to opioids.
Morphine and other opioids increase the activity of the locomotor centers in the brain, which control the mice's movements, by raising levels of the neurotransmitter dopamine. This seems to be related to their addictive properties. But "conolidine does not affect locomotor activity, suggesting that it does not induce dopamine elevations", says Bohn. One of the goals now, she adds, is to identify just how conolidine does suppress pain.
Even if conolidine proves a success in clinical trials, it remains to be seen whether Micalizio's synthesis will be the way to make it on a large scale. But, he says, "we believe that this is certainly a good start". He also suspects that this won't be the only potential drug to come from the family of compounds produced by this plant.
This article is reproduced with permission from the magazine Nature. The article was first published on May 3, 2011.